NBIX Earnings Date 2026
Neurocrine Biosciences Inc earnings schedule and quarterly results
Next Earnings Date
TBD
Current Stock Price
$153.88
-0.12% today
Earnings Metrics
EPS (TTM)
$4.19
P/E Ratio
31.6
Revenue Growth
27.8%
Market Cap
$13.2B
Earnings History
| Quarter | EPS | Revenue | Net Income |
|---|---|---|---|
| Q4 2024 | $3.40 | $2.36B | $0.34B |
| Q4 2023 | $2.56 | $1.89B | $0.25B |
Trading Around NBIX Earnings
Before Earnings
- Review analyst expectations and consensus estimates
- Check options implied volatility for expected move
- Consider historical earnings surprises
- Monitor pre-announcement guidance
After Earnings
- Compare actual results to estimates
- Listen to the earnings call for guidance
- Watch for analyst rating changes
- Monitor institutional buying/selling
Get Full NBIX Analysis
DCF valuation, AI insights, and institutional ownership data
Frequently Asked Questions
When is NBIX next earnings date?
NBIX (Neurocrine Biosciences Inc) has not yet announced its next earnings date. Check back for updates on the upcoming earnings schedule.
What is NBIX earnings per share (EPS)?
NBIX's current earnings per share (EPS) is $4.19. With a P/E ratio of 31.6, the market values each dollar of earnings at $31.6.
How often does NBIX report earnings?
Like most publicly traded US companies, NBIX (Neurocrine Biosciences Inc) reports earnings quarterly, typically within 4-6 weeks after each fiscal quarter ends. The company holds an earnings call to discuss results with analysts.
What time does NBIX report earnings?
NBIX typically reports earnings either before market open (BMO) or after market close (AMC). The exact time is usually announced a few days before the earnings date. Check the investor relations page for specific timing.
How has NBIX performed in recent earnings?
In the most recent quarter (Q4 2024), NBIX reported EPS of $3.40 on revenue of $2.36B.
What do analysts expect for NBIX earnings?
Analyst expectations for NBIX earnings can vary. The company has shown positive revenue growth of 27.8%. View the full analyst ratings page for detailed expectations.